Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. DIAGNOS Inc.
  6. News
  7. Summary
    ADK   CA2524423068

DIAGNOS INC.

(ADK)
  Report
Delayed Bourse de Toronto  -  03:02:04 2023-01-27 pm EST
0.3400 CAD    0.00%
01/25DIAGNOS Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
CI
01/13DIAGNOS Announces Closing of Private Placement
GL
01/13DIAGNOS Inc. announced that it has received CAD 0.25 million in funding
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

DIAGNOS : 2020-04-27, DIAGNOS Provides Update on its CARA AI Application Participating in US White House Call to Action Data Analysis Program – Download PDF

04/27/2020 | 10:23am EST

2020.04.27

DIAGNOS Provides Update on its CARA AI Application Participating in US White House Call to Action Data Analysis Program

Brossard, Quebec, Canada - April 27th, 2020 - DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues using advanced Artificial Intelligence (AI) tools, provides an update on its CARA (Computer Assisted Retinal Analysis) AI Application, following the Corporation's participation in the US White House call to action data analysis program ("Program"), as referred to in the Corporation's March 25, 2020 press release. Pursuant to the Corporation's analysis of the technical details sourced from the Program, it is developing a new add-on test to CARA to provide an innovative solution for COVID-19 patients by offering a means to monitor health through retina analysis. DIAGNOS' scientific team has been able to link the Corporation's core business application of its CARA technology for early onset of blindness caused by Diabetes to assess the effects of COVID-19 on patients.

In an effort to help patients exposed to the COVID-19 virus, DIAGNOS is formulating a test by means of its CARA application to monitor the short and long-term effects of the virus through retina analysis and its proprietary advanced detection algorithm. In the Open Research Dataset (CORD-19), DIAGNOS has identified evidence of the impact of certain medication that affects the retina of the eye, more specifically diabetic patients. This dataset continues to provide valuable information that address questions DIAGNOS is exploring in order to increase the functionality of its CARA application, for instance analyzing the tendency for asymptomatic patients to develop increased retinopathy symptoms that DIAGNOS could subsequently identify.

Mr. André Larente, CEO of DIAGNOS stated: "Through the use of the information contained in the CORD-19 dataset we have gathered from the US government Call-to-action", DIAGNOS' AI platform is currently being modified in order to add innovative testing tools to help identify the effects of the COVID-19 virus. The AAO (American Academy of Ophthalmology) has already identified certain medications that clearly demonstrate an impact on the retina. Through the use of a fundus test, such as the one that we provide, we could add a test for this specific pathology. We are testing our technology to see if we can eventually provide the proper solution to build on our existing tests tools."

About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence ("AI") platform FLAIRE. Using the FLAIRE platform, DIAGNOS is able to build and further extend rapidly its applications such as CARA (Computer Assisted Retina Analysis). CARA's Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is a cost-effective tool for screening a large number of patients in real-time and has been cleared for commercialization by several regulatory authorities including Health Canada, the U.S. Food and Drug Administration, European Union and other countries.

Additional information is available at www.diagnos.comand www.sedar.com.

2

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Mr. André Larente, President DIAGNOS Inc.

Tel: 450-678-8882 ext. 224 alarente@diagnos.ca

- 30 -

Disclaimer

Diagnos Inc. published this content on 27 April 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2020 14:22:05 UTC


ę Publicnow 2020
All news about DIAGNOS INC.
01/25DIAGNOS Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Decem..
CI
01/13DIAGNOS Announces Closing of Private Placement
GL
01/13DIAGNOS Inc. announced that it has received CAD 0.25 million in funding
CI
2022DIAGNOS Provides Additional Information to the Closing of Private Placement
AQ
2022Diagnos Raises C$0.35 Million in the Second Tranche of a Private Placement of Debenture..
MT
2022DIAGNOS Announces Closing of Private Placement
AQ
2022DIAGNOS Inc. announced that it has received CAD 0.85 million in funding
CI
2022DIAGNOS Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Septe..
CI
2022Diagnos Closes C$0.5-Million Private Placement of Convertible-Debenture Units
MT
2022DIAGNOS Announces Closing of Private Placement
GL
More news
Financials
Sales 2023 0,60 M 0,45 M 0,45 M
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -11,3x
Yield 2023 -
Capitalization 23,6 M 17,7 M 17,7 M
Capi. / Sales 2023 39,6x
Capi. / Sales 2024 8,39x
Nbr of Employees 22
Free-Float 83,7%
Chart DIAGNOS INC.
Duration : Period :
DIAGNOS Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,34 CAD
Average target price 1,00 CAD
Spread / Average Target 194%
EPS Revisions
Managers and Directors
AndrÚ M. Larente President, Chief Executive Officer & Director
Marc-AndrÚ Massue Chief Financial Officer, Secretary & VP-Finance
Vincent Duhamel Chairman
Reid Maclellan Independent Director
Francis Bellido Independent Director
Sector and Competitors